C‐peptide is associated with NAFLD inflammatory and fibrotic progression in type 2 diabetes
Background A higher prevalence of nonalcoholic steatohepatitis (NASH) and advanced stages of fibrosis was observed in type 2 diabetes. We aim to investigate whether C‐peptide is associated with nonalcoholic fatty liver disease (NAFLD) progression in type 2 diabetic adults. Methods A total of 4937 di...
Gespeichert in:
Veröffentlicht in: | Diabetes/metabolism research and reviews 2020-02, Vol.36 (2), p.e3210-n/a |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background
A higher prevalence of nonalcoholic steatohepatitis (NASH) and advanced stages of fibrosis was observed in type 2 diabetes. We aim to investigate whether C‐peptide is associated with nonalcoholic fatty liver disease (NAFLD) progression in type 2 diabetic adults.
Methods
A total of 4937 diabetic participants were enrolled from China in 2018. Liver steatosis was detected by ultrasound. Subjects with NAFLD were categorized into simple NAFLD and probable NASH by the concurrent presence of metabolic syndrome. NAFLD fibrosis score was used to identify patients with probable advanced fibrosis.
Results
Individuals with a longer history of type 2 diabetes had a lower C‐peptide level and a lower prevalence of probable NASH but a higher prevalence of advanced fibrosis. C‐peptide was positively associated with simple NAFLD and probable NASH, with odds ratios (ORs) of 4.55 [95% confidence interval (CI) 3.16, 6.55] and 5.28 (95% CI 3.94, 7.09), respectively, comparing quartile 4 with quartile 1 (both p for trend |
---|---|
ISSN: | 1520-7552 1520-7560 |
DOI: | 10.1002/dmrr.3210 |